Three Publications Demonstrate Bionano's OGM's Utility For Cell And Gene Therapy; Publications Include Niño Jesús University Children's Hospital; Ruhr-University Bochum And Janssen

• Three peer-reviewed publications collectively illustrate the building support for optical genome mapping (OGM) as a tool for cell and gene therapy development that allows researchers in academic medical centers and biopharmaceutical companies to assess genome integrity in therapeutic cell lines like chimeric antigen receptor-modified T cells (CAR-T), stem cells, and cell lines used for translational research in unraveling genetic causes of Alzheimer's disease
• Taken together, the publications illustrate that OGM can be highly sensitive for genome-wide detection of on and off target effects that may limit the utility of stem cell lines and CAR-T cell products

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication of three studies which collectively illustrate the continued development of data supporting the utility of optical genome mapping (OGM) in cell and gene therapy applications. In all three publications, the authors note OGM's potential to provide a comprehensive landscape of genome structure and to assess genome integrity due to the workflow's ability to detect structural variants (SVs) with higher sensitivity and resolution than standard cytogenetic techniques.